Zafgen, Inc (ZFGN)

Trade ZFGN now with
11/7/2017 4:37:05 PM Zafgen Posts Q3 Net Loss Of $12.6 Mln Or $0.46/share
10/10/2017 7:08:03 AM Zafgen Appoints Jeffrey Hatfield As CEO; Thomas Hughes, To Continue As President, Appointed Chief Scientific Officer
9/12/2017 8:19:36 AM Zafgen Presents New Preclinical Data On ZGN-1061
5/4/2017 4:22:01 PM Zafgen Trading Expected To Resume At 4:30 PM ET
5/4/2017 4:05:23 PM Zafgen Trading Halted; Pending News
9/20/2016 7:06:59 AM Zafgen Initiates Multiple Ascending Dose Cohorts In Phase 1 Clinical Trial Of ZGN-1061
7/20/2016 9:32:27 AM FBR Capital Markets Is Raising Zafgen, Inc (ZFGN) 2017 Estimate To -1.48 From -2.85
7/20/2016 9:31:37 AM FBR Capital Markets Cuts Zafgen, Inc (ZFGN) To Market Perform From Outperform With $5 Down From $20 Price Target